Oncology Biomarkers
Cancer remains a significant health challenge in New Zealand, with more than 30,000 people expected to be diagnosed each year in 2025 and projections suggesting this could rise to over 45,000 by 2044 as the population ages and risk factors persist. Accurate and timely biomarker testing is a cornerstone of modern oncology, informing diagnosis, prognosis, treatment selection and ongoing monitoring.
Translyx is bringing emerging molecular and protein-based biomarker technologies into the New Zealand market that align with international advances in precision oncology. These solutions help clinicians understand tumour biology more deeply, match patients to the most appropriate therapies, and adapt treatment plans based on response. By improving access to validated biomarkers and next generation molecular assays, Translyx aims to support earlier detection, personalised treatment pathways, and better long-term outcomes for people affected by cancer in Aotearoa and beyond.